Literature DB >> 29794855

An overview of the cannabinoid type 2 receptor system and its therapeutic potential.

Bihua Bie1, Jiang Wu, Joseph F Foss, Mohamed Naguib.   

Abstract

PURPOSE OF REVIEW: This narrative review summarizes recent insights into the role of the cannabinoid type 2 (CB2) receptor as potential therapeutic target in neuropathic pain and neurodegenerative conditions. RECENT
FINDINGS: The cannabinoid system continues to receive attention as a therapeutic target. The CB2 receptor is primarily expressed on glial cells only when there is active inflammation and appears to be devoid of undesired psychotropic effects or addiction liability. The CB2 receptor has been shown to have potential as a therapeutic target in models of diseases with limited or no currently approved therapies, such as neuropathic pain and neurodegenerative conditions such as Alzheimer's disease.
SUMMARY: The functional involvement of CB2 receptor in neuropathic pain and other neuroinflammatory diseases highlights the potential therapeutic role of drugs acting at the CB2 receptor.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29794855      PMCID： PMC6035094          DOI： 10.1097/ACO.0000000000000616

Source DB:  PubMed          Journal:  Curr Opin Anaesthesiol        ISSN： 0952-7907            Impact factor:   2.706


  107 in total

1.  Role of microglia in mechanical allodynia in the anterior cingulate cortex.

Authors:  Keisuke Miyamoto; Kazuhiko Kume; Masahiro Ohsawa
Journal:  J Pharmacol Sci       Date:  2017-06-21       Impact factor: 3.337

2.  Activation of inwardly rectifying potassium channels (GIRK1) by co-expressed rat brain cannabinoid receptors in Xenopus oocytes.

Authors:  D J Henry; C Chavkin
Journal:  Neurosci Lett       Date:  1995-02-17       Impact factor: 3.046

3.  Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity.

Authors:  Douglas Osei-Hyiaman; Michael DePetrillo; Pál Pacher; Jie Liu; Svetlana Radaeva; Sándor Bátkai; Judith Harvey-White; Ken Mackie; László Offertáler; Lei Wang; George Kunos
Journal:  J Clin Invest       Date:  2005-05       Impact factor: 14.808

4.  Counter-regulation of opioid analgesia by glial-derived bioactive sphingolipids.

Authors:  Carolina Muscoli; Tim Doyle; Concetta Dagostino; Leesa Bryant; Zhoumou Chen; Linda R Watkins; Jan Ryerse; Erhard Bieberich; William Neumman; Daniela Salvemini
Journal:  J Neurosci       Date:  2010-11-17       Impact factor: 6.167

5.  Evaluation of the analgesic efficacy and psychoactive effects of AZD1940, a novel peripherally acting cannabinoid agonist, in human capsaicin-induced pain and hyperalgesia.

Authors:  Jarkko Kalliomäki; Peter Annas; Karin Huizar; Cyril Clarke; Annika Zettergren; Rolf Karlsten; Märta Segerdahl
Journal:  Clin Exp Pharmacol Physiol       Date:  2013-03       Impact factor: 2.557

6.  TIPE2, a negative regulator of innate and adaptive immunity that maintains immune homeostasis.

Authors:  Honghong Sun; Shunyou Gong; Ruaidhri J Carmody; Anja Hilliard; Li Li; Jing Sun; Li Kong; Lingyun Xu; Brendan Hilliard; Shimin Hu; Hao Shen; Xiaolu Yang; Youhai H Chen
Journal:  Cell       Date:  2008-05-02       Impact factor: 41.582

7.  Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats.

Authors:  Elizabeth J Rahn; Alexander M Zvonok; Ganesh A Thakur; Atmaram D Khanolkar; Alexandros Makriyannis; Andrea G Hohmann
Journal:  J Pharmacol Exp Ther       Date:  2008-07-29       Impact factor: 4.030

8.  Cannabinoid Type 2 Receptors Mediate a Cell Type-Specific Plasticity in the Hippocampus.

Authors:  A Vanessa Stempel; Alexander Stumpf; Hai-Ying Zhang; Tuğba Özdoğan; Ulrike Pannasch; Anne-Kathrin Theis; David-Marian Otte; Alexandra Wojtalla; Ildikó Rácz; Alexey Ponomarenko; Zheng-Xiong Xi; Andreas Zimmer; Dietmar Schmitz
Journal:  Neuron       Date:  2016-04-28       Impact factor: 17.173

9.  The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis.

Authors:  Daniela Cota; Giovanni Marsicano; Matthias Tschöp; Yvonne Grübler; Cornelia Flachskamm; Mirjam Schubert; Dorothee Auer; Alexander Yassouridis; Christa Thöne-Reineke; Sylvia Ortmann; Federica Tomassoni; Cristina Cervino; Enzo Nisoli; Astrid C E Linthorst; Renato Pasquali; Beat Lutz; Günter K Stalla; Uberto Pagotto
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808

10.  MDA7: a novel selective agonist for CB2 receptors that prevents allodynia in rat neuropathic pain models.

Authors:  M Naguib; P Diaz; J J Xu; F Astruc-Diaz; S Craig; P Vivas-Mejia; D L Brown
Journal:  Br J Pharmacol       Date:  2008-09-01       Impact factor: 8.739
View more
  23 in total

Review 1.  Endocannabinoid system and its modulation of brain, gut, joint and skin inflammation.

Authors:  Newman Osafo; Oduro K Yeboah; Aaron O Antwi
Journal:  Mol Biol Rep       Date:  2021-04-28       Impact factor: 2.316

2.  Candidate Therapeutics by Screening for Multitargeting Ligands: Combining the CB2 Receptor With CB1, PPARγ and 5-HT4 Receptors.

Authors:  Shayma El-Atawneh; Amiram Goldblum
Journal:  Front Pharmacol       Date:  2022-02-28       Impact factor: 5.810

3.  A CB2 Receptor Agonist Reduces the Production of Inflammatory Mediators and Improves Locomotor Activity in Experimental Autoimmune Encephalomyelitis.

Authors:  Karim Parastouei; Mohammad Hossein Aarabi; Gholam Ali Hamidi; Zahra Nasehi; Shima Kabiri-Arani; Faezeh Jozi; Mohammad Esmaeil Shahaboddin
Journal:  Rep Biochem Mol Biol       Date:  2022-04

Review 4.  The effects of cannabis and cannabinoids on the endocrine system.

Authors:  Farah Meah; Michelle Lundholm; Nicholas Emanuele; Hafsa Amjed; Caroline Poku; Lily Agrawal; Mary Ann Emanuele
Journal:  Rev Endocr Metab Disord       Date:  2021-08-30       Impact factor: 9.306

Review 5.  The Endocannabinoid System as a Therapeutic Target in Diabetic Peripheral Neuropathic Pain: A Review.

Authors:  Amina M Bagher
Journal:  J Microsc Ultrastruct       Date:  2021-05-24

6.  Effects of active, inactive, and derivatives of Akkermansia muciniphila on the expression of the endocannabinoid system and PPARs genes.

Authors:  Farinaz Ghaderi; Fattah Sotoodehnejadnematalahi; Zahra Hajebrahimi; Abolfazl Fateh; Seyed Davar Siadat
Journal:  Sci Rep       Date:  2022-06-15       Impact factor: 4.996

Review 7.  Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids.

Authors:  Dennis J Sholler; Marilyn A Huestis; Benjamin Amendolara; Ryan Vandrey; Ziva D Cooper
Journal:  Pharmacol Biochem Behav       Date:  2020-10-18       Impact factor: 3.533

8.  Protective role of neuronal and lymphoid cannabinoid CB2 receptors in neuropathic pain.

Authors:  David Cabañero; Angela Ramírez-López; Eva Drews; Anne Schmöle; David M Otte; Agnieszka Wawrzczak-Bargiela; Hector Huerga Encabo; Sami Kummer; Antonio Ferrer-Montiel; Ryszard Przewlocki; Andreas Zimmer; Rafael Maldonado
Journal:  Elife       Date:  2020-07-20       Impact factor: 8.140

9.  Structure-Based Identification of Potent Natural Product Chemotypes as Cannabinoid Receptor 1 Inverse Agonists.

Authors:  Pankaj Pandey; Kuldeep K Roy; Haining Liu; Guoyi Ma; Sara Pettaway; Walid F Alsharif; Rama S Gadepalli; John M Rimoldi; Christopher R McCurdy; Stephen J Cutler; Robert J Doerksen
Journal:  Molecules       Date:  2018-10-13       Impact factor: 4.411

Review 10.  Progress in PET Imaging of Neuroinflammation Targeting COX-2 Enzyme.

Authors:  Jaya Prabhakaran; Andrei Molotkov; Akiva Mintz; J John Mann
Journal:  Molecules       Date:  2021-05-27       Impact factor: 4.411
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.